JP7670462B2 - 選択的グルココルチコイドレセプターモジュレーターを使用して神経上皮腫瘍を処置する方法 - Google Patents

選択的グルココルチコイドレセプターモジュレーターを使用して神経上皮腫瘍を処置する方法 Download PDF

Info

Publication number
JP7670462B2
JP7670462B2 JP2019570000A JP2019570000A JP7670462B2 JP 7670462 B2 JP7670462 B2 JP 7670462B2 JP 2019570000 A JP2019570000 A JP 2019570000A JP 2019570000 A JP2019570000 A JP 2019570000A JP 7670462 B2 JP7670462 B2 JP 7670462B2
Authority
JP
Japan
Prior art keywords
group
glucocorticoid receptor
tumor
composition
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019570000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524152A5 (enExample
JP2020524152A (ja
Inventor
アンドレアス ジー． モライティス，
Original Assignee
コーセプト セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コーセプト セラピューティクス， インコーポレイテッド filed Critical コーセプト セラピューティクス， インコーポレイテッド
Publication of JP2020524152A publication Critical patent/JP2020524152A/ja
Publication of JP2020524152A5 publication Critical patent/JP2020524152A5/ja
Priority to JP2022136739A priority Critical patent/JP2022164775A/ja
Priority to JP2025026258A priority patent/JP2025071259A/ja
Application granted granted Critical
Publication of JP7670462B2 publication Critical patent/JP7670462B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019570000A 2017-06-20 2018-06-18 選択的グルココルチコイドレセプターモジュレーターを使用して神経上皮腫瘍を処置する方法 Active JP7670462B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022136739A JP2022164775A (ja) 2017-06-20 2022-08-30 選択的グルココルチコイドレセプターモジュレーターを使用して神経上皮腫瘍を処置する方法
JP2025026258A JP2025071259A (ja) 2017-06-20 2025-02-20 選択的グルココルチコイドレセプターモジュレーターを使用して神経上皮腫瘍を処置する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762522489P 2017-06-20 2017-06-20
US62/522,489 2017-06-20
PCT/US2018/038075 WO2018236749A2 (en) 2017-06-20 2018-06-18 Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2022136739A Division JP2022164775A (ja) 2017-06-20 2022-08-30 選択的グルココルチコイドレセプターモジュレーターを使用して神経上皮腫瘍を処置する方法
JP2025026258A Division JP2025071259A (ja) 2017-06-20 2025-02-20 選択的グルココルチコイドレセプターモジュレーターを使用して神経上皮腫瘍を処置する方法

Publications (3)

Publication Number Publication Date
JP2020524152A JP2020524152A (ja) 2020-08-13
JP2020524152A5 JP2020524152A5 (enExample) 2021-07-26
JP7670462B2 true JP7670462B2 (ja) 2025-04-30

Family

ID=64737393

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019570000A Active JP7670462B2 (ja) 2017-06-20 2018-06-18 選択的グルココルチコイドレセプターモジュレーターを使用して神経上皮腫瘍を処置する方法
JP2022136739A Pending JP2022164775A (ja) 2017-06-20 2022-08-30 選択的グルココルチコイドレセプターモジュレーターを使用して神経上皮腫瘍を処置する方法
JP2025026258A Pending JP2025071259A (ja) 2017-06-20 2025-02-20 選択的グルココルチコイドレセプターモジュレーターを使用して神経上皮腫瘍を処置する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022136739A Pending JP2022164775A (ja) 2017-06-20 2022-08-30 選択的グルココルチコイドレセプターモジュレーターを使用して神経上皮腫瘍を処置する方法
JP2025026258A Pending JP2025071259A (ja) 2017-06-20 2025-02-20 選択的グルココルチコイドレセプターモジュレーターを使用して神経上皮腫瘍を処置する方法

Country Status (8)

Country Link
US (3) US11213526B2 (enExample)
EP (1) EP3641780B1 (enExample)
JP (3) JP7670462B2 (enExample)
AU (1) AU2018289307B2 (enExample)
CA (1) CA3065555A1 (enExample)
ES (1) ES3043682T3 (enExample)
MX (1) MX393313B (enExample)
WO (1) WO2018236749A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3641780B1 (en) 2017-06-20 2025-09-10 Corcept Therapeutics Incorporated Treatment of neuroepithelial tumors using selective glucocorticoid receptor modulators
JP7196201B2 (ja) 2018-06-04 2022-12-26 コーセプト セラピューティクス， インコーポレイテッド ピリミジンシクロヘキセニル糖質コルチコイドレセプター調節因子
JP7516394B2 (ja) 2019-01-22 2024-07-16 アクリベス ビオメディカル ゲーエムベーハー 皮膚創傷治癒不全を治療するための選択的グルココルチコイド受容体モジュレーター
AU2021266739B2 (en) 2020-05-06 2024-11-28 Corcept Therapeutics Incorporated Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators
CA3182272A1 (en) 2020-05-06 2021-11-11 Corcept Therapeutics Incorporated Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators
KR20230124020A (ko) 2020-12-21 2023-08-24 코어셉트 쎄라퓨틱스 인코포레이티드 피리미딘 시클로헥실 글루코코르티코이드 수용체 조절제의제조 방법
WO2024050500A1 (en) * 2022-09-02 2024-03-07 Corcept Therapeutics Incorporated Methods of assessing selective glucocorticoid receptor modulation and of identifying and treating patients likely to benefit from glucocorticoid receptor modulation
WO2025255357A1 (en) * 2024-06-06 2025-12-11 Corcept Therapeutics Incorporated Methods for preparing and maintaining livers and portions thereof for liver transplantation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150010503A1 (en) 2012-02-24 2015-01-08 The University Of Chicago Methods and Compositions Related to Glucocorticoid Receptor Antagonism and Prostate Cancer
WO2016140867A1 (en) 2015-03-02 2016-09-09 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4296206A (en) 1980-04-30 1981-10-20 United States Of America Irreversible anti-glucocorticoids
US4978657A (en) 1981-01-09 1990-12-18 Roussel Uclaf Novel 11β-substituted-19-nor-steroids
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2528434B1 (fr) 1982-06-11 1985-07-19 Roussel Uclaf Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament
FR2522328B1 (fr) 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
FR2639045B2 (fr) 1982-03-01 1994-07-29 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto-delta-4,9-19-nor steroides et leur application comme medicaments
DE3438994A1 (de) 1984-10-22 1986-04-24 Schering AG, Berlin und Bergkamen, 1000 Berlin Antigestagene, glukokortikoide und prostaglandine zur geburtseinleitung oder fuer den schwangerschaftsabbruch
FR2576025B1 (fr) 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
AU580843B2 (en) 1985-02-07 1989-02-02 Schering Aktiengesellschaft 11``-phenyl-gonanes, their manufacture and pharmaceutical preparations containing them
DE3506785A1 (de) 1985-02-22 1986-08-28 Schering AG, Berlin und Bergkamen, 1000 Berlin 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
US5380840A (en) 1985-09-12 1995-01-10 The Upjohn Company Triazinylpiperazinyl steroids
FR2598421B1 (fr) 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
DE3761308D1 (de) 1986-07-23 1990-02-08 Akzo Nv 18-phenylestrane-derivate.
DE3625315A1 (de) 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
US4861763A (en) 1986-09-17 1989-08-29 Research Triangle Institute 17 α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and their progestational use
US4774236A (en) 1986-09-17 1988-09-27 Research Triangle Institute 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US4921638A (en) 1986-11-05 1990-05-01 The Upjohn Company 17β-cyano-9α,17α-dihydroxyandrost-4-en-3-one
DE3708942A1 (de) 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3723788A1 (de) 1987-07-16 1989-01-26 Schering Ag 11(beta)-phenyl-4,9,15-estratriene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2618783B1 (fr) 1987-07-30 1991-02-01 Roussel Uclaf Nouveaux 17-aryle steroides, leurs procedes et des intermediaires de preparation comme medicaments et les compositions pharmaceutiques les renfermant
JP2785023B2 (ja) 1987-12-30 1998-08-13 ルセル―ユクラフ １７α位置を置換された１７β―ＯＨ―１９―ノルステロイドの新誘導体、その製造方法、その薬剤としての使用及びそれを含有する製薬組成物
DE3820948A1 (de) 1988-06-16 1989-12-21 Schering Ag 10ss, 11ss-ueberbrueckte steroide
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5348729A (en) 1988-11-30 1994-09-20 The United States Of America As Represented By The Department Of Health And Human Services Evaluative means for detecting inflammatory reactivity
DD289541A5 (de) 1989-08-04 1991-05-02 ��@�K@�������������@�K@��������������@��������k�� Verfahren zur herstellung von 11beta-aryl-16 alpha, 17 alph-cyclohexanoestra-4,9-dienen
US5276023A (en) 1989-08-08 1994-01-04 Roussel Uclaf 19-nor-steroid esters
FR2651233B1 (fr) 1989-08-23 1991-12-13 Roussel Uclaf Nouveaux acides omega-phenylamino alcanouiques substitues sur le noyau aromatique par un radical derive de 19-norsterouides, leur procede de preparation, leur application a titre de medicaments et les compositions les renfermant.
US5173405A (en) 1990-01-23 1992-12-22 The United States Of America As Represented By The Department Of Health And Human Services Use of arsenite to reversibly block steroid binding to glucocorticoid receptors in the presence of other steroid receptors
US5616458A (en) 1990-03-14 1997-04-01 Board Of Regents, University Of Tx System Tripterygium wilfordii hook F extracts and components, and uses thereof
DE4042004A1 (de) 1990-12-22 1992-06-25 Schering Ag 14(beta)-h-, 14- u. 15-en-11(beta)-aryl-4-estrene
US5215916A (en) 1991-06-19 1993-06-01 The United States Of America As Represented By The Department Of Health & Human Services Super glucocorticoid receptors: receptors with increased affinity and specificity for glucocorticoid steriods
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
ZA953976B (en) 1994-05-19 1996-01-19 Akzo Nobel Nv 11,21-bisphenyl-19-norpregnane derivatives
US6051573A (en) 1994-06-28 2000-04-18 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with non-steroidal glucocorticoid antagonists
DE69531998T2 (de) 1994-12-22 2004-07-22 Ligand Pharmaceuticals, Inc., San Diego Steroidrezeptor-modulator verbindungen und methoden
US5688808A (en) 1994-12-22 1997-11-18 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
IL118974A (en) 1995-08-17 2001-09-13 Akzo Nobel Nv History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them
US5929058A (en) 1996-12-24 1999-07-27 Zymogenetics, Inc. Treatment agents and methods for treating type II diabetes and symptoms of type II diabetes
EP0903146A1 (en) 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid
DE10038639A1 (de) 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
IL180679A0 (en) 2000-10-27 2009-02-11 Pfizer Prod Inc Process for the preparation of non-steroidal glucocorticoid receptor modulators
AU2002366217A1 (en) 2001-11-23 2003-06-10 Akzo Nobel N.V. Treatment of major depressive disorder using glucocorticoid receptor antagonists
PT1735308E (pt) 2004-03-09 2008-12-02 Corcept Therapeutics Inc Moduladores dos receptores de glucocorticóides de azadecalina de anel fundido
US20060205700A1 (en) * 2005-03-09 2006-09-14 May Flavia S Non invasive method for prevention and treatment of cancer
EP2429529B1 (en) 2009-05-12 2015-01-14 Corcept Therapeutics, Inc. Solid forms and process for preparing
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
US8710035B2 (en) 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
JP6039587B2 (ja) * 2011-03-18 2016-12-07 コーセプト セラピューティクス， インコーポレイテッド ピリミジンシクロヘキシルグルココルチコイドレセプター調節因子
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
PL3590517T3 (pl) 2012-05-25 2021-09-20 Corcept Therapeutics Incorporated Modulatory receptorów glukokortykoidowych typu azadekaliny skondensowanej z heteroaryloketonem
US8986677B2 (en) 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods
BR112016011826B1 (pt) 2013-11-25 2022-09-27 Corcept Therapeutics, Inc Composto, composição farmacêutica e uso do referido composto
IL297201A (en) * 2016-03-01 2022-12-01 Corcept Therapeutics Inc Use of glucocorticoid receptor modulators to increase the activity of checkpoint inhibitors
WO2018209142A2 (en) * 2017-05-10 2018-11-15 Corcept Therapeutics, Inc. Octahydro azadecalin formulations
EP3641780B1 (en) * 2017-06-20 2025-09-10 Corcept Therapeutics Incorporated Treatment of neuroepithelial tumors using selective glucocorticoid receptor modulators

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150010503A1 (en) 2012-02-24 2015-01-08 The University Of Chicago Methods and Compositions Related to Glucocorticoid Receptor Antagonism and Prostate Cancer
WO2016140867A1 (en) 2015-03-02 2016-09-09 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cancer Res., 2016, Vol. 76, Issue 4_Supplement, PD3-02
Gynecologic Oncology, 2015, Vol. 138, p. 656-662
Journal of Neurology, Neurosurgery and Psychiatry, 1992, Vol. 55, p. 486-490

Also Published As

Publication number Publication date
US11213526B2 (en) 2022-01-04
EP3641780A4 (en) 2021-02-24
JP2022164775A (ja) 2022-10-27
EP3641780A2 (en) 2020-04-29
EP3641780B1 (en) 2025-09-10
CA3065555A1 (en) 2018-12-27
US20200147082A1 (en) 2020-05-14
US11793810B2 (en) 2023-10-24
WO2018236749A3 (en) 2019-01-24
JP2025071259A (ja) 2025-05-02
US20220079946A1 (en) 2022-03-17
ES3043682T3 (en) 2025-11-25
MX393313B (es) 2025-03-24
AU2018289307B2 (en) 2024-02-01
US12263169B2 (en) 2025-04-01
AU2018289307A1 (en) 2019-12-19
US20240009194A1 (en) 2024-01-11
WO2018236749A2 (en) 2018-12-27
JP2020524152A (ja) 2020-08-13

Similar Documents

Publication Publication Date Title
JP7670462B2 (ja) 選択的グルココルチコイドレセプターモジュレーターを使用して神経上皮腫瘍を処置する方法
JP7174083B2 (ja) 膵臓癌を処置するためのグルココルチコイドレセプターモジュレーター
US10898478B2 (en) Glucocorticoid receptor modulators to treat cervical cancer
CN113490496A (zh) 一种杂芳基-酮稠合氮杂萘烷糖皮质激素受体调节剂瑞拉可兰的治疗用途
HK40027249B (en) Treatment of neuroepithelial tumors using selective glucocorticoid receptor modulators
HK40027249A (en) Treatment of neuroepithelial tumors using selective glucocorticoid receptor modulators
HK40058363A (en) Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
HK40015342B (en) Glucocorticoid receptor modulators to treat cervical cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220830

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250417

R150 Certificate of patent or registration of utility model

Ref document number: 7670462

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150